|
US3773719A
(en)
|
1966-12-06 |
1973-11-20 |
Hoffmann La Roche |
2-aminoxy-2'-acyl-acetanilide
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
DE3785186T2
(de)
|
1986-09-02 |
1993-07-15 |
Enzon Lab Inc |
Bindungsmolekuele mit einzelpolypeptidkette.
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
|
US5322678A
(en)
|
1988-02-17 |
1994-06-21 |
Neorx Corporation |
Alteration of pharmacokinetics of proteins by charge modification
|
|
CS269411B1
(en)
|
1988-09-14 |
1990-04-11 |
Ales Manek |
Device for yearn's interruption
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
ATE185601T1
(de)
|
1990-07-10 |
1999-10-15 |
Cambridge Antibody Tech |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
|
WO1993012227A1
(en)
|
1991-12-17 |
1993-06-24 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
WO1992003918A1
(en)
|
1990-08-29 |
1992-03-19 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
HU218140B
(hu)
|
1991-04-25 |
2000-06-28 |
Chugai Seiyaku Kabushiki Kaisha |
Humán interleukin-6-receptorral szembeni átalakított humán antitest
|
|
WO1993006213A1
(en)
|
1991-09-23 |
1993-04-01 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
US6027725A
(en)
|
1991-11-25 |
2000-02-22 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
DK1024191T3
(da)
|
1991-12-02 |
2008-12-08 |
Medical Res Council |
Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
|
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
|
EP0656941B1
(en)
|
1992-03-24 |
2005-06-01 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
SG48760A1
(en)
|
1992-07-24 |
2003-03-18 |
Abgenix Inc |
Generation of xenogenetic antibodies
|
|
ZA936260B
(en)
|
1992-09-09 |
1994-03-18 |
Smithkline Beecham Corp |
Novel antibodies for conferring passive immunity against infection by a pathogen in man
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US5648267A
(en)
|
1992-11-13 |
1997-07-15 |
Idec Pharmaceuticals Corporation |
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
|
|
AU6819494A
(en)
|
1993-04-26 |
1994-11-21 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
GB9313509D0
(en)
|
1993-06-30 |
1993-08-11 |
Medical Res Council |
Chemisynthetic libraries
|
|
WO1995015388A1
(en)
|
1993-12-03 |
1995-06-08 |
Medical Research Council |
Recombinant binding proteins and peptides
|
|
DE122009000068I2
(de)
|
1994-06-03 |
2011-06-16 |
Ascenion Gmbh |
Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
|
|
AU701342B2
(en)
|
1994-07-13 |
1999-01-28 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstituted human antibody against human interleukin-8
|
|
US6309636B1
(en)
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
|
CA2201781C
(en)
|
1994-10-07 |
2010-01-12 |
Tadamitsu Kishimoto |
Chronic rheumatoid arthritis therapy containing il-6 antagonist as effective component
|
|
RU2147442C1
(ru)
|
1994-10-21 |
2000-04-20 |
Кисимото Тадамицу |
Фармацевтическая композиция для профилактики или лечения заболеваний, вызываемых образованием il-6
|
|
US6485943B2
(en)
|
1995-01-17 |
2002-11-26 |
The University Of Chicago |
Method for altering antibody light chain interactions
|
|
CA2210309C
(en)
|
1995-02-28 |
2002-04-16 |
The Procter & Gamble Company |
Preparation of noncarbonated beverage products having superior microbial stability
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
AU5632296A
(en)
|
1995-04-27 |
1996-11-18 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
CA2219486A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
DE69633973T2
(de)
|
1995-09-11 |
2005-12-22 |
Kyowa Hakko Kogyo Co., Ltd. |
Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
|
|
CZ399A3
(cs)
|
1996-07-19 |
1999-06-16 |
Amgen Inc. |
Polypeptidová analoga kationaktivních polypeptidů
|
|
US5990286A
(en)
|
1996-12-18 |
1999-11-23 |
Techniclone, Inc. |
Antibodies with reduced net positive charge
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
JP4213224B2
(ja)
|
1997-05-02 |
2009-01-21 |
ジェネンテック，インコーポレーテッド |
ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
|
|
US20030207346A1
(en)
*
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
JP3992298B2
(ja)
|
1997-10-03 |
2007-10-17 |
中外製薬株式会社 |
天然ヒト型化抗体
|
|
ES2364266T3
(es)
|
1998-04-03 |
2011-08-30 |
Chugai Seiyaku Kabushiki Kaisha |
Anticuerpo humanizado hacia el factor tisular humano (tf) y procedimiento para construir el anticuerpo humanizado.
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
WO2000018806A1
(de)
|
1998-09-25 |
2000-04-06 |
Horst Lindhofer |
Bispezifische und trispezifische antikörper, die spezifisch mit induzierbaren oberflächenantigenen als operationelle zielstrukturen reagieren
|
|
AU764211C
(en)
|
1998-12-01 |
2006-03-30 |
Abbvie Biotherapeutics Inc. |
Humanized antibodies to gamma-interferon
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL220113B1
(pl)
|
1999-01-15 |
2015-08-31 |
Genentech Inc |
Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
|
|
US6972125B2
(en)
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
SE9903895D0
(sv)
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
|
MXPA02010801A
(es)
|
2000-05-03 |
2004-09-06 |
Munich Biotech Ag |
Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados.
|
|
CA2409991A1
(en)
|
2000-05-24 |
2001-11-29 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
|
ES2727425T3
(es)
|
2000-12-12 |
2019-10-16 |
Medimmune Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
BRPI0209792B8
(pt)
|
2001-04-13 |
2021-05-25 |
Biogen Idec Inc |
anticorpo anti-vla-1, composição que o compreende, ácido nucléico e vetor, bem como métodos in vitro para determinar o nível de vla-1 em tecido e para identificar inibidor de domínio i de integrina
|
|
ATE483801T1
(de)
|
2001-06-22 |
2010-10-15 |
Chugai Pharmaceutical Co Ltd |
Zellproliferationshemmer, die anti-glypican 3 antikörper enthalten
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
US20030049203A1
(en)
|
2001-08-31 |
2003-03-13 |
Elmaleh David R. |
Targeted nucleic acid constructs and uses related thereto
|
|
ES2326964T3
(es)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
Composiciones de glicoproteina.
|
|
KR20040082421A
(ko)
|
2002-02-11 |
2004-09-24 |
제넨테크, 인크. |
빠른 항원 결합 속도를 갖는 항체 변이체
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
WO2003074679A2
(en)
|
2002-03-01 |
2003-09-12 |
Xencor |
Antibody optimization
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7736652B2
(en)
|
2002-03-21 |
2010-06-15 |
The Regents Of The University Of California |
Antibody fusion proteins: effective adjuvants of protein vaccination
|
|
EP1510943A4
(en)
|
2002-05-31 |
2007-05-09 |
Celestar Lexico Sciences Inc |
INTERACTION PREDICTION DEVICE
|
|
JP2004086862A
(ja)
|
2002-05-31 |
2004-03-18 |
Celestar Lexico-Sciences Inc |
タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体
|
|
US7750204B2
(en)
|
2002-06-05 |
2010-07-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing antibody
|
|
EP1517921B1
(en)
|
2002-06-28 |
2006-06-07 |
Domantis Limited |
Dual specific ligands with increased serum half-life
|
|
EP1539947A4
(en)
|
2002-08-15 |
2006-09-06 |
Epitomics Inc |
HUMANIZED RABBIT ANTIBODIES
|
|
AU2002328429A1
(en)
|
2002-09-04 |
2004-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
EP1558648B1
(en)
|
2002-10-17 |
2012-01-11 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
US8337841B2
(en)
|
2003-01-21 |
2012-12-25 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of screening for antibody light chains
|
|
JP2006517109A
(ja)
|
2003-02-07 |
2006-07-20 |
プロテイン デザイン ラブス インコーポレイテッド |
アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
|
MXPA05012723A
(es)
|
2003-05-30 |
2006-02-08 |
Genentech Inc |
Tratamiento con anticuerpos anti-vgf.
|
|
PT1631313E
(pt)
|
2003-06-05 |
2015-07-02 |
Genentech Inc |
Terapêutica de combinação para distúrbios de células b
|
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
|
EP2385069A3
(en)
|
2003-11-12 |
2012-05-30 |
Biogen Idec MA Inc. |
Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
|
WO2005063815A2
(en)
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
ES2641831T3
(es)
|
2003-12-10 |
2017-11-14 |
E. R. Squibb & Sons, L.L.C. |
Anticuerpos contra interferón alfa y sus usos
|
|
CA2550996A1
(en)
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
|
TWI363762B
(en)
|
2004-01-09 |
2012-05-11 |
Pfizer |
Antibodies to madcam
|
|
CA2561264A1
(en)
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
WO2005112564A2
(en)
|
2004-04-15 |
2005-12-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Germline and sequence variants of humanized antibodies and methods of making and using them
|
|
SG155883A1
(en)
|
2004-06-03 |
2009-10-29 |
Novimmune Sa |
Anti-cd3 antibodies and methods of use thereof
|
|
KR100620554B1
(ko)
|
2004-06-05 |
2006-09-06 |
한국생명공학연구원 |
Ｔａｇ-72에 대한 인간화 항체
|
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
|
CA2572133A1
(en)
|
2004-06-25 |
2006-01-12 |
Medimmune, Inc. |
Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
|
|
CN111925445A
(zh)
|
2004-07-09 |
2020-11-13 |
中外制药株式会社 |
抗-磷脂酰肌醇蛋白聚糖3抗体
|
|
PL2471813T3
(pl)
|
2004-07-15 |
2015-09-30 |
Xencor Inc |
Zoptymalizowane warianty Fc
|
|
WO2006020114A2
(en)
|
2004-08-04 |
2006-02-23 |
Applied Molecular Evolution, Inc. |
Variant fc regions
|
|
MX2007002856A
(es)
|
2004-09-02 |
2007-09-25 |
Genentech Inc |
Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
|
|
MX2007002883A
(es)
|
2004-09-13 |
2007-06-15 |
Macrogenics Inc |
Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo.
|
|
EP1799718A1
(en)
|
2004-09-14 |
2007-06-27 |
National Institute for Biological Standards and Control (NIBSC) |
Vaccine
|
|
US20060074225A1
(en)
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
|
WO2006067847A1
(ja)
|
2004-12-22 |
2006-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
|
|
CA2595169A1
(en)
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
|
EP1870458B1
(en)
|
2005-03-31 |
2018-05-09 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2 STRUCTURAL ISOMERS
|
|
WO2006105338A2
(en)
|
2005-03-31 |
2006-10-05 |
Xencor, Inc. |
Fc VARIANTS WITH OPTIMIZED PROPERTIES
|
|
WO2006106905A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
会合制御によるポリペプチド製造方法
|
|
DK1876236T3
(da)
|
2005-04-08 |
2014-10-20 |
Chugai Pharmaceutical Co Ltd |
Antistof som funktionel erstatning for blodkoagulationsfaktor VIII
|
|
JP5047947B2
(ja)
|
2005-05-05 |
2012-10-10 |
デューク ユニバーシティ |
自己免疫疾患のための抗ｃｄ１９抗体治療
|
|
AU2006256030B2
(en)
|
2005-06-10 |
2012-06-21 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical compositions containing sc(Fv)2
|
|
US20090028854A1
(en)
|
2005-06-10 |
2009-01-29 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2 SITE-DIRECTED MUTANT
|
|
EP3327033A1
(en)
|
2005-08-19 |
2018-05-30 |
Wyeth LLC |
Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
|
|
WO2007060411A1
(en)
|
2005-11-24 |
2007-05-31 |
Ucb Pharma S.A. |
Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
|
|
EP1820513A1
(en)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
|
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
|
JP5474531B2
(ja)
|
2006-03-24 |
2014-04-16 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
操作されたヘテロ二量体タンパク質ドメイン
|
|
IN2014DN10515A
(enExample)
|
2006-03-31 |
2015-08-21 |
Chugai Pharmaceutical Co Ltd |
|
|
WO2007114325A1
(ja)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
二重特異性抗体を精製するための抗体改変方法
|
|
JP2009539841A
(ja)
|
2006-06-06 |
2009-11-19 |
トラークス，インコーポレイテッド |
自己免疫疾患の治療における抗ｃｄ３抗体の投与
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
EP2107115A1
(en)
|
2007-01-24 |
2009-10-07 |
Kyowa Hakko Kirin Co., Ltd. |
Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
|
|
AU2008230795B2
(en)
|
2007-03-27 |
2014-05-29 |
Bioassets, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
|
AU2008234248C1
(en)
|
2007-03-29 |
2015-01-22 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
EP2144931A2
(en)
|
2007-04-04 |
2010-01-20 |
The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services |
Monoclonal antibodies against dengue and other viruses with deletion in fc region
|
|
WO2008145142A1
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Stable igg4 antibodies
|
|
WO2009006112A1
(en)
|
2007-06-29 |
2009-01-08 |
Schering Corporation |
Mdl-1 uses
|
|
HUE028737T2
(en)
|
2007-07-17 |
2017-01-30 |
Squibb & Sons Llc |
Monoclonal antibodies against glypican-3
|
|
PL3059246T3
(pl)
|
2007-09-26 |
2018-11-30 |
Chugai Seiyaku Kabushiki Kaisha |
Zmodyfikowany region stały przeciwciała
|
|
CN101939425B
(zh)
|
2007-09-26 |
2014-05-14 |
中外制药株式会社 |
抗il-6受体抗体
|
|
AU2008304778B9
(en)
|
2007-09-26 |
2014-05-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in CDR
|
|
CN101809162B
(zh)
|
2007-09-28 |
2013-06-05 |
中外制药株式会社 |
血浆中动力学被改善的磷脂酰肌醇蛋白聚糖3抗体
|
|
JP5314033B2
(ja)
|
2007-10-22 |
2013-10-16 |
メルク セローノ ソシエテ アノニム |
突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
MX350962B
(es)
|
2008-01-07 |
2017-09-27 |
Amgen Inc |
Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
|
|
PL2274008T3
(pl)
|
2008-03-27 |
2014-07-31 |
Zymogenetics Inc |
Kompozycje i sposoby hamowania PDGFRbeta i VEGF-A
|
|
HRP20160209T1
(hr)
|
2008-04-11 |
2016-03-25 |
Chugai Pharmaceutical Co Ltd |
Antigenski vežuća molekula koja se može višekratno vezati na dva ili više antigena
|
|
EP2899209A1
(en)
|
2008-04-29 |
2015-07-29 |
Abbvie Inc. |
Dual Variable Domain Immunoglobulins and uses thereof
|
|
AU2009296297A1
(en)
|
2008-09-26 |
2010-04-01 |
Roche Glycart Ag |
Bispecific anti-EGFR/anti-IGF-1R antibodies
|
|
WO2010042904A2
(en)
|
2008-10-10 |
2010-04-15 |
Trubion Pharmaceuticals, Inc. |
Tcr complex immunotherapeutics
|
|
DE202008016028U1
(de)
|
2008-12-04 |
2010-04-15 |
Melitta Haushaltsprodukte Gmbh & Co. Kg |
Behälter zur Aufbewahrung von Gegenständen
|
|
US20120100140A1
(en)
|
2009-01-23 |
2012-04-26 |
Biogen Idec Ma Inc. |
Stabilized fc polypeptides with reduced effector function and methods of use
|
|
NZ594514A
(en)
|
2009-03-05 |
2013-06-28 |
Abbott Lab |
Interleukin-17 BINDING PROTEINS
|
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
EP3674317B1
(en)
|
2009-03-19 |
2024-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
|
RU2587621C2
(ru)
|
2009-04-01 |
2016-06-20 |
Дженентек, Инк. |
АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
ES2537100T3
(es)
|
2009-04-07 |
2015-06-02 |
Roche Glycart Ag |
Anticuerpos biespecíficos trivalentes
|
|
CN102459346B
(zh)
|
2009-04-27 |
2016-10-26 |
昂考梅德药品有限公司 |
制造异源多聚体分子的方法
|
|
PL2975051T3
(pl)
|
2009-06-26 |
2021-09-20 |
Regeneron Pharmaceuticals, Inc. |
Wyizolowane z łatwością dwuswoiste przeciwciała o formacie natywnej immunoglobuliny
|
|
AU2010286518C1
(en)
|
2009-08-29 |
2015-08-27 |
Abbvie Inc. |
Therapeutic DLL4 binding proteins
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
US10053513B2
(en)
|
2009-11-30 |
2018-08-21 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
|
ES2777901T3
(es)
|
2009-12-25 |
2020-08-06 |
Chugai Pharmaceutical Co Ltd |
Método de modificación de polipéptidos para purificar multímeros polipeptídicos
|
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
JP5820800B2
(ja)
|
2010-03-02 |
2015-11-24 |
協和発酵キリン株式会社 |
改変抗体組成物
|
|
WO2011108714A1
(ja)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
KR20120138241A
(ko)
|
2010-03-11 |
2012-12-24 |
화이자 인코포레이티드 |
ｐＨ 의존성 항원 결합을 갖는 항체
|
|
HRP20241208T1
(hr)
|
2010-04-20 |
2024-11-22 |
Genmab A/S |
Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
|
|
CA2796633C
(en)
|
2010-04-23 |
2020-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
WO2011143545A1
(en)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
CA2800785C
(en)
|
2010-05-27 |
2019-09-24 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
JP2013537416A
(ja)
|
2010-08-13 |
2013-10-03 |
メディミューン リミテッド |
変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
|
|
JP5997154B2
(ja)
|
2010-08-16 |
2016-09-28 |
ノビミューン エスアー |
多重特異性多価抗体の生成方法
|
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
|
KR102447595B1
(ko)
|
2010-11-30 |
2022-09-26 |
추가이 세이야쿠 가부시키가이샤 |
세포상해 유도 치료제
|
|
EP3539991A1
(en)
|
2011-01-07 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Method for improving physical properties of antibody
|
|
DK2698431T3
(da)
|
2011-03-30 |
2020-11-30 |
Chugai Pharmaceutical Co Ltd |
Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet
|
|
CN104114579B
(zh)
|
2011-10-27 |
2020-01-24 |
健玛保 |
异二聚体蛋白的生成
|
|
WO2013065708A1
(ja)
|
2011-10-31 |
2013-05-10 |
中外製薬株式会社 |
重鎖と軽鎖の会合が制御された抗原結合分子
|
|
US9574010B2
(en)
|
2011-11-04 |
2017-02-21 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
CA2871068C
(en)
|
2012-04-20 |
2022-06-14 |
Merus B.V. |
Methods and means for the production of ig-like molecules
|
|
RU2673153C2
(ru)
|
2012-04-20 |
2018-11-22 |
АПТЕВО РИСЁРЧ ЭНД ДИВЕЛОПМЕНТ ЭлЭлСи |
Полипептиды, связывающиеся с cd3
|
|
AU2013258834B2
(en)
|
2012-05-10 |
2017-09-07 |
Zymeworks Bc Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
|
|
US9409994B2
(en)
*
|
2012-06-01 |
2016-08-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High-affinity monoclonal antibodies to glypican-3 and use thereof
|
|
CN104640561A
(zh)
|
2012-07-23 |
2015-05-20 |
酵活有限公司 |
包含轻链和重链的选择性配对的免疫球蛋白构建体
|
|
KR20150041662A
(ko)
|
2012-08-13 |
2015-04-16 |
리제너론 파아마슈티컬스, 인크. |
Ｐｈ-의존적 결합 특성을 갖는 항-ｐｃｓｋ9 항체
|
|
JOP20200236A1
(ar)
*
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
JP6471095B2
(ja)
|
2012-09-27 |
2019-02-20 |
メルス ナムローゼ フェンノートシャップ |
Ｔ細胞エンゲージャーとしての二重特異性ＩｇＧ抗体
|
|
JP6273205B2
(ja)
|
2012-10-05 |
2018-01-31 |
協和発酵キリン株式会社 |
ヘテロダイマータンパク質組成物
|
|
EP2914634B1
(en)
|
2012-11-02 |
2017-12-06 |
Zymeworks Inc. |
Crystal structures of heterodimeric fc domains
|
|
CN103833852A
(zh)
|
2012-11-23 |
2014-06-04 |
上海市肿瘤研究所 |
针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
|
|
RU2730594C2
(ru)
|
2013-09-27 |
2020-08-24 |
Чугаи Сейяку Кабусики Кайся |
Способ получения полипептидного гетеромультимера
|
|
EP3037525B1
(en)
|
2013-09-30 |
2021-06-02 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing antigen-binding molecule using modified helper phage
|
|
WO2015156268A1
(ja)
|
2014-04-07 |
2015-10-15 |
中外製薬株式会社 |
免疫活性化抗原結合分子
|
|
CA2947157A1
(en)
|
2014-05-13 |
2015-11-19 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
|
MA40764A
(fr)
*
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
|
EP3320773B9
(en)
|
2015-07-10 |
2023-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
Mouse having human cd3 gene substituted for endogenous cd3 gene
|
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
RU2746754C2
(ru)
|
2016-03-14 |
2021-04-20 |
Чугаи Сейяку Кабусики Кайся |
Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
|
|
JP6175590B1
(ja)
|
2016-03-14 |
2017-08-02 |
中外製薬株式会社 |
癌の治療に用いるための細胞傷害誘導治療剤
|
|
CR20210381A
(es)
|
2017-09-29 |
2021-09-09 |
Chugai Pharmaceutical Co Ltd |
MOLÉCULA DE UNIÓN AL ANTÍGENO MULTIESPECÍFICA QUE TIENE ACTIVIDAD DE SUSTITUCIÓN DE LA FUNCIÓN DE COFACTOR DEL FACTOR VIII DE COAGULACIÓN DE SANGRE (FVIII) Y FORMULACIÓN FARMACÉUTICA QUE CONTIENE TAL MOLÉCULA COMO INGREDIENTE (Divisional Exp. 2020-0158)
|
|
WO2019131988A1
(en)
|
2017-12-28 |
2019-07-04 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
|
MY205856A
(en)
|
2018-05-16 |
2024-11-15 |
Stichting Vumc |
Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
|